A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Wugen, Inc.
Beijing Biotech
Bristol-Myers Squibb
Guangzhou Bio-gene Technology Co., Ltd
Gyala Therapeutics
OneChain Immunotherapeutics
Ossium Health, Inc.
Servier
SymBio Pharmaceuticals
Daiichi Sankyo
Otsuka Medical Devices Co., Ltd. Japan
Wugen, Inc.